B细胞-话题@MedSci

#B细胞#

314篇内容 | 6935人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273347, encodeId=7e1a12e334754, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要, objectType=article, longId=190315, objectId=76131903158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76131903158c, replyNumber=0, likeNumber=68, createdTime=2020-03-20, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76131903158c, moduleTitle=Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76131903158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273346, encodeId=339b12e33466d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育, objectType=article, longId=189802, objectId=897e18980253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=897e18980253, replyNumber=0, likeNumber=104, createdTime=2020-03-13, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=897e18980253, moduleTitle=Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=897e18980253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273345, encodeId=c0a612e334569, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2020.V1）, objectType=article, longId=188974, objectId=ae461889e4c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae461889e4c5, replyNumber=0, likeNumber=60, createdTime=2020-03-01, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae461889e4c5, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae461889e4c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273344, encodeId=49d312e3344ac, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化, objectType=article, longId=188594, objectId=2de618859436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de618859436, replyNumber=0, likeNumber=138, createdTime=2020-02-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de618859436, moduleTitle=J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de618859436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=91, createdTime=2020-02-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273342, encodeId=977312e334223, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, objectType=article, longId=188100, objectId=0b4e188100f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4e188100f8, replyNumber=0, likeNumber=94, createdTime=2020-02-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4e188100f8, moduleTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4e188100f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273341, encodeId=d08012e334121, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, objectType=article, longId=187714, objectId=782818e714bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782818e714bf, replyNumber=0, likeNumber=81, createdTime=2020-02-10, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782818e714bf, moduleTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782818e714bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273340, encodeId=40cb12e334013, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, objectType=article, longId=187601, objectId=3fc418e60132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc418e60132, replyNumber=0, likeNumber=118, createdTime=2020-02-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc418e60132, moduleTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc418e60132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273339, encodeId=9c5112e33399e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=79, createdTime=2020-02-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273338, encodeId=e5a212e333895, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, objectType=article, longId=186397, objectId=d68418639efd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68418639efd, replyNumber=0, likeNumber=96, createdTime=2020-01-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68418639efd, moduleTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68418639efd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273337, encodeId=753e12e333740, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, objectType=article, longId=186322, objectId=1d521863220b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d521863220b, replyNumber=0, likeNumber=97, createdTime=2020-01-17, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d521863220b, moduleTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d521863220b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273336, encodeId=fdbd12e3336fd, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关, objectType=article, longId=186313, objectId=7b171863132c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b171863132c, replyNumber=0, likeNumber=82, createdTime=2020-01-17, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b171863132c, moduleTitle=Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b171863132c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273335, encodeId=3f9212e333586, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, objectType=article, longId=186206, objectId=9fb1186206ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb1186206ed, replyNumber=0, likeNumber=79, createdTime=2020-01-15, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb1186206ed, moduleTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb1186206ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273334, encodeId=dba812e333461, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=83, createdTime=2020-01-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273333, encodeId=cece12e33338a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）, objectType=article, longId=185482, objectId=aa7a18548291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7a18548291, replyNumber=0, likeNumber=29, createdTime=2020-01-01, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7a18548291, moduleTitle=NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7a18548291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273332, encodeId=e3d812e33325d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, objectType=article, longId=185165, objectId=014518516583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=014518516583, replyNumber=0, likeNumber=137, createdTime=2019-12-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=014518516583, moduleTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=014518516583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273331, encodeId=a95a12e3331a3, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, objectType=article, longId=185002, objectId=956e185002ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956e185002ad, replyNumber=0, likeNumber=90, createdTime=2019-12-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956e185002ad, moduleTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956e185002ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273330, encodeId=1f0c12e33307d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型, objectType=article, longId=184217, objectId=58b418421ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b418421ed6, replyNumber=0, likeNumber=79, createdTime=2019-12-07, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b418421ed6, moduleTitle=Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b418421ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=135, createdTime=2019-11-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, objectType=article, longId=182246, objectId=c8d018224602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8d018224602, replyNumber=0, likeNumber=83, createdTime=2019-11-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8d018224602, moduleTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8d018224602)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要

2020-03-20

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育

2020-03-13

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：B细胞淋巴瘤（2020.V1）

2020-03-01

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化

2020-02-24

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-02-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查

2020-02-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤

2020-02-10

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响

2020-02-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤

2020-01-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛

2020-01-17

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关

2020-01-17

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战

2020-01-15

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）

2020-01-01

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？

2019-12-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤

2019-12-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型

2019-12-07

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发

2019-11-03

科室
- - 订阅+
  - 更多科室
工具
服务